Ampliphi Biosciences Corp Common (GREY:APHBD)

For the fourth quarter of 2009, the Company reported net income of $1.8 million, or $0.08 per common share, compared to a net loss of $10.8 million, or $0.54 per common share, for the fourth quarter of 2008. For the year ended December 31, 2009, the Company reported net income of $7.9 million, or $0.39 per common share, compared to a net loss of $20.7 million, or $1.04 per common share, for the year ended December 31, 2008. Per share results for 2008 include a non-cash goodwill impairment charge of $7.9 million recognized in the fourth quarter of 2008.

The Company’s results for 2009 reflect the September 2009 sale and license of certain assets, including manufacturing technologies and adeno-associated viral vector (AAV) technologies to Genzyme Corporation, delivery of MYDICAR® product candidate to its partner Celladon Corporation and the successful settlement of the Company’s Bothell, Washington facility lease.